A detailed history of Parallel Advisors, LLC transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Parallel Advisors, LLC holds 1,511 shares of SAGE stock, worth $8,280. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,511
Previous 152 894.08%
Holding current value
$8,280
Previous $1,000 900.0%
% of portfolio
0.0%
Previous 0.0%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$7.02 - $13.08 $9,540 - $17,775
1,359 Added 894.08%
1,511 $10,000
Q2 2024

Aug 08, 2024

SELL
$10.58 - $17.9 $8,844 - $14,964
-836 Reduced 84.62%
152 $1,000
Q4 2023

Feb 09, 2024

BUY
$17.1 - $22.26 $7,404 - $9,638
433 Added 78.02%
988 $21,000
Q3 2023

May 20, 2024

BUY
$16.75 - $48.98 $7,520 - $21,992
449 Added 423.58%
555 $11,000
Q3 2023

Nov 13, 2023

BUY
$16.75 - $48.98 $7,520 - $21,992
449 Added 423.58%
555 $11,000
Q2 2023

May 20, 2024

BUY
$40.65 - $59.54 $243 - $357
6 Added 6.0%
106 $4,000
Q2 2023

Aug 04, 2023

BUY
$40.65 - $59.54 $243 - $357
6 Added 6.0%
106 $4,000
Q1 2023

May 20, 2024

SELL
$37.27 - $46.57 $33,095 - $41,354
-888 Reduced 89.88%
100 $4,000
Q4 2022

Feb 03, 2023

SELL
$32.2 - $43.61 $225 - $305
-7 Reduced 6.54%
100 $3,000
Q3 2022

Nov 10, 2022

SELL
$32.28 - $43.27 $1,323 - $1,774
-41 Reduced 27.7%
107 $4,000
Q2 2022

Aug 01, 2022

BUY
$27.52 - $37.99 $4,072 - $5,622
148 New
148 $5,000
Q1 2022

Apr 28, 2022

SELL
$30.71 - $45.71 $5,404 - $8,044
-176 Closed
0 $0
Q4 2021

Jan 20, 2022

SELL
$37.06 - $47.11 $1,408 - $1,790
-38 Reduced 17.76%
176 $7,000
Q3 2021

Nov 02, 2021

BUY
$40.26 - $57.37 $4,187 - $5,966
104 Added 94.55%
214 $9,000
Q3 2020

Oct 27, 2020

BUY
$41.13 - $62.45 $3,701 - $5,620
90 Added 450.0%
110 $7,000
Q2 2020

Jul 16, 2020

SELL
$25.95 - $43.15 $3,918 - $6,515
-151 Reduced 88.3%
20 $0
Q1 2020

Apr 27, 2020

BUY
$26.15 - $77.24 $4,471 - $13,208
171 New
171 $4,000
Q4 2019

Jan 30, 2020

SELL
$60.18 - $154.77 $1,624 - $4,178
-27 Closed
0 $0
Q1 2019

May 01, 2019

BUY
$89.33 - $163.65 $2,411 - $4,418
27 New
27 $4,000
Q4 2018

Feb 05, 2019

SELL
$81.94 - $139.71 $737 - $1,257
-9 Closed
0 $0
Q3 2018

Nov 01, 2018

SELL
$138.11 - $169.04 $1,104 - $1,352
-8 Reduced 47.06%
9 $1,000
Q2 2018

Jul 30, 2018

SELL
$140.36 - $175.76 $561 - $703
-4 Reduced 19.05%
17 $2,000
Q1 2018

May 08, 2018

BUY
$152.15 - $192.33 $3,195 - $4,038
21 New
21 $3,000

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $326M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Parallel Advisors, LLC Portfolio

Follow Parallel Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.